Capricor Therapeutics, Inc. Faces Securities Lawsuit Over Alleged Fraud

Strategic Insights -

Capricor Therapeutics, Inc. (NASDAQ: CAPR) has been involved in a class action securities lawsuit alleging securities fraud, filed on behalf of shareholders who suffered losses between October 9, 2024, and July 10, 2025. The complaint alleges that defendants provided investors with misleading information regarding Capricor's lead cell therapy candidate, deramiocel, for treating cardiomyopathy associated with Duchenne muscular dystrophy. The company's statements about obtaining a Biologics License Application (BLA) from the FDA were deemed false and misleading, as they concealed material adverse facts about the four-year safety and efficacy data from the Phase 2 HOPE-2 trial study. Upon receiving a Complete Response Letter (CRL) from the FDA, citing the need for additional clinical data, the price of Capricor stock plummeted from $11.40 to $7.64 per share.

Key Takeaways:

  • Capricor Therapeutics, Inc. has been named as a defendant in a class action securities lawsuit filed on behalf of shareholders who suffered losses between October 9, 2024, and July 10, 2025.
  • Defendants allegedly provided investors with misleading information regarding the company's lead cell therapy candidate, deramiocel, for treating cardiomyopathy associated with Duchenne muscular dystrophy.
  • The complaint alleges that Capricor's statements about obtaining a Biologics License Application (BLA) from the FDA were false and misleading, as they concealed material adverse facts about the four-year safety and efficacy data from the Phase 2 HOPE-2 trial study.
  • The price of Capricor stock declined from $11.40 per share on July 10, 2025, to $7.64 per share on July 11, 2025, following a Complete Response Letter (CRL) from the FDA.
  • The litigation firm Levi & Korsinsky, LLP is representing investors in the lawsuit and has a track record of securing hundreds of millions of dollars for aggrieved shareholders.
  • The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve clients.

Statistics:

  • Date range of alleged securities fraud: October 9, 2024, to July 10, 2025.
  • Price decline of Capricor stock: $11.40 to $7.64 per share.
  • Alleged losses suffered by shareholders.

Sources:

  • Newsfile Corp., "Capricor Therapeutics, Inc. [CAPR] Lawsuit on behalf of investors who suffered losses from NASDAQ: CAPR stock."
  • Levi & Korsinsky, LLP, "Capricor Therapeutics, Inc. Lawsuit Submission Form."